Skip to main content
Top
Published in: Supportive Care in Cancer 2/2015

01-02-2015 | Original Article

Changes in medication profile among patients with advanced cancer admitted to an acute palliative care unit

Authors: David Hui, Zhijun Li, Gary B. Chisholm, Neha Didwaniya, Eduardo Bruera

Published in: Supportive Care in Cancer | Issue 2/2015

Login to get access

Abstract

Purpose

The decision-making process for medication use in the last weeks of life is complex because of patient frailty and poor prognosis. Limited literature is available on medication use in the palliative care setting, particularly in acute palliative care units (APCUs). We examined the changes in medication profile among hospitalized patients with advanced cancer before their palliative care inpatient consultation team referral, after palliative care consultation, at the time of APCU admission, and at APCU discharge or death.

Methods

We included consecutive patients with advanced cancer who were first seen by our inpatient palliative care consultation team and subsequently admitted to the APCU. We retrieved data on all scheduled medications at the prespecified time points.

Results

Among the 100 patients, the median duration of hospitalization was 10.5 days (interquartile range 8–15 days), and the median APCU stay was 5 days (interquartile range 3–7 days). The average number of medications before palliative care inpatient consultation team referral, after palliative care consultation, at APCU admission and at APCU discharge/death was 9.2 (standard deviation [SD] 4.5), 9.9 (SD 4.2), 10.3 (SD 3.8), and 10.1 (SD 3.8), respectively (P = 0.03). An increasing proportion of patients received medications for symptom control over their course of hospitalization, including systemic corticosteroids, laxatives, neuroleptics, and antiulcer agents (P < 0.05). In contrast, the frequency of several classes of medications such as antihypertensives, antilipemics, and anticonvulsants decreased over time (P < 0.05).

Conclusions

Palliative care involvement was associated with an increase in symptom control medications and decrease in medications for comorbid conditions over time.
Literature
1.
go back to reference Bailey FA, Williams BR, Woodby LL, Goode PS, Redden DT, Houston TK, Granstaff US, Johnson TM 2nd, Pennypacker LC, Haddock KS, Painter JM, Spencer JM, Hartney T, Burgio KL (2014) Intervention to improve care at life’s end in inpatient settings: the BEACON Trial. J Gen Intern Med 29(6):836–843PubMedCrossRef Bailey FA, Williams BR, Woodby LL, Goode PS, Redden DT, Houston TK, Granstaff US, Johnson TM 2nd, Pennypacker LC, Haddock KS, Painter JM, Spencer JM, Hartney T, Burgio KL (2014) Intervention to improve care at life’s end in inpatient settings: the BEACON Trial. J Gen Intern Med 29(6):836–843PubMedCrossRef
2.
go back to reference Casarett D, Johnson M, Smith D, Richardson D (2011) The optimal delivery of palliative care: a national comparison of the outcomes of consultation teams vs inpatient units. Arch Intern Med 171(7):649–655PubMedCrossRef Casarett D, Johnson M, Smith D, Richardson D (2011) The optimal delivery of palliative care: a national comparison of the outcomes of consultation teams vs inpatient units. Arch Intern Med 171(7):649–655PubMedCrossRef
3.
go back to reference Cohen SR, Boston P, Mount BM, Porterfield P (2001) Changes in quality of life following admission to palliative care units. Palliat Med 15(5):363–371PubMedCrossRef Cohen SR, Boston P, Mount BM, Porterfield P (2001) Changes in quality of life following admission to palliative care units. Palliat Med 15(5):363–371PubMedCrossRef
4.
go back to reference Fang CK, Chen HW, Liu SI, Lin CJ, Tsai LY, Lai YL (2008) Prevalence, detection and treatment of delirium in terminal cancer inpatients: a prospective survey. Jpn J Clin Oncol 38(1):56–63PubMedCrossRef Fang CK, Chen HW, Liu SI, Lin CJ, Tsai LY, Lai YL (2008) Prevalence, detection and treatment of delirium in terminal cancer inpatients: a prospective survey. Jpn J Clin Oncol 38(1):56–63PubMedCrossRef
5.
go back to reference Hui D, Bruera E (2014) Internal medicine issues in palliative cancer care. In: Internal medicine issues in palliative cancer care. Oxford University Press, Oxford Hui D, Bruera E (2014) Internal medicine issues in palliative cancer care. In: Internal medicine issues in palliative cancer care. Oxford University Press, Oxford
6.
go back to reference Hui D, Elsayem A, De la Cruz M, Berger A, Zhukovsky DS, Palla S, Evans A, Fadul N, Palmer JL, Bruera E (2010) Availability and integration of palliative care at US cancer centers. JAMA 303(11):1054–1061PubMedCentralPubMedCrossRef Hui D, Elsayem A, De la Cruz M, Berger A, Zhukovsky DS, Palla S, Evans A, Fadul N, Palmer JL, Bruera E (2010) Availability and integration of palliative care at US cancer centers. JAMA 303(11):1054–1061PubMedCentralPubMedCrossRef
7.
go back to reference Hui D, Elsayem A, Li Z, De La Cruz M, Palmer JL, Bruera E (2010) Antineoplastic therapy use in patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center: a simultaneous care model. Cancer 116(8):2036–2043PubMedCentralPubMedCrossRef Hui D, Elsayem A, Li Z, De La Cruz M, Palmer JL, Bruera E (2010) Antineoplastic therapy use in patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center: a simultaneous care model. Cancer 116(8):2036–2043PubMedCentralPubMedCrossRef
8.
go back to reference Hui D, Reddy A, Palla S, Bruera E (2011) Neuroleptic prescription pattern for delirium in patients with advanced cancer. J Palliat Care 27(2):141–147PubMed Hui D, Reddy A, Palla S, Bruera E (2011) Neuroleptic prescription pattern for delirium in patients with advanced cancer. J Palliat Care 27(2):141–147PubMed
9.
go back to reference Jenkins CA, Schulz M, Hanson J, Bruera E (2000) Demographic, symptom, and medication profiles of cancer patients seen by a palliative care consult team in a tertiary referral hospital. J Pain Symptom Manag 19(3):174–184CrossRef Jenkins CA, Schulz M, Hanson J, Bruera E (2000) Demographic, symptom, and medication profiles of cancer patients seen by a palliative care consult team in a tertiary referral hospital. J Pain Symptom Manag 19(3):174–184CrossRef
10.
go back to reference Jenkins CA, Taube AW, Turner K, Hanson J, Bruera E (1998) Initial demographic, symptom, and medication profiles in patients admitted to continuing palliative care units. J Pain Symptom Manag 16(3):163–170CrossRef Jenkins CA, Taube AW, Turner K, Hanson J, Bruera E (1998) Initial demographic, symptom, and medication profiles in patients admitted to continuing palliative care units. J Pain Symptom Manag 16(3):163–170CrossRef
11.
go back to reference Lundy E, McMullan D, McShane P, Williams M, Watson M, White C (2013) Polypharmacy and drug omissions across hospices in Northern Ireland. J Palliat Med 16(11):1446–1449PubMedCrossRef Lundy E, McMullan D, McShane P, Williams M, Watson M, White C (2013) Polypharmacy and drug omissions across hospices in Northern Ireland. J Palliat Med 16(11):1446–1449PubMedCrossRef
12.
go back to reference National Consensus Project for Quality Palliative Care (2009) Clinical practice guidelines for quality palliative care. In: Clinical practice guidelines for quality palliative care. Second edition. National Consensus Project for Quality Palliative Care, Pittsburg National Consensus Project for Quality Palliative Care (2009) Clinical practice guidelines for quality palliative care. In: Clinical practice guidelines for quality palliative care. Second edition. National Consensus Project for Quality Palliative Care, Pittsburg
13.
go back to reference Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwohner K, Schulenberg D, Radbruch L (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18(2):100–107PubMedCrossRef Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwohner K, Schulenberg D, Radbruch L (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18(2):100–107PubMedCrossRef
14.
go back to reference Raijmakers NJ, van Zuylen L, Furst CJ, Beccaro M, Maiorana L, Pilastri P, Rossi C, Flego G, van der Heide A, Costantini M (2012) Variation in medication use in cancer patients at the end of life: a cross-sectional analysis. Support Care Cancer 21(4):1003–1011PubMedCrossRef Raijmakers NJ, van Zuylen L, Furst CJ, Beccaro M, Maiorana L, Pilastri P, Rossi C, Flego G, van der Heide A, Costantini M (2012) Variation in medication use in cancer patients at the end of life: a cross-sectional analysis. Support Care Cancer 21(4):1003–1011PubMedCrossRef
15.
go back to reference Rashidi NM, Zordan RD, Flynn E, Philip JA (2011) The care of the very old in the last three days of life. J Palliat Med 14(12):1339–1344PubMedCrossRef Rashidi NM, Zordan RD, Flynn E, Philip JA (2011) The care of the very old in the last three days of life. J Palliat Med 14(12):1339–1344PubMedCrossRef
16.
go back to reference Riechelmann RP, Krzyzanowska MK, O’Carroll A, Zimmermann C (2007) Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 15(12):1407–1412PubMedCrossRef Riechelmann RP, Krzyzanowska MK, O’Carroll A, Zimmermann C (2007) Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 15(12):1407–1412PubMedCrossRef
17.
go back to reference Riechelmann RP, Krzyzanowska MK, Zimmermann C (2009) Futile medication use in terminally ill cancer patients. Support Care Cancer 17(6):745–748PubMedCrossRef Riechelmann RP, Krzyzanowska MK, Zimmermann C (2009) Futile medication use in terminally ill cancer patients. Support Care Cancer 17(6):745–748PubMedCrossRef
18.
go back to reference Taylor R, Bryant M, Chadwick S (2011) What a waste! Futile prescribing and the cost of wasted medication at the end of life. BMJ Support Palliat Care 1(2):225CrossRef Taylor R, Bryant M, Chadwick S (2011) What a waste! Futile prescribing and the cost of wasted medication at the end of life. BMJ Support Palliat Care 1(2):225CrossRef
19.
go back to reference Twycross RG, Bergl S, John S, Lewis K (1994) Monitoring drug use in palliative care. Palliat Med 8(2):137–143PubMedCrossRef Twycross RG, Bergl S, John S, Lewis K (1994) Monitoring drug use in palliative care. Palliat Med 8(2):137–143PubMedCrossRef
20.
go back to reference Vitetta L, Kenner D, Sali A (2005) Sedation and analgesia-prescribing patterns in terminally ill patients at the end of life. Am J Hosp Palliat Care 22(6):465–473PubMed Vitetta L, Kenner D, Sali A (2005) Sedation and analgesia-prescribing patterns in terminally ill patients at the end of life. Am J Hosp Palliat Care 22(6):465–473PubMed
21.
go back to reference Wooldridge JE, Anderson CM, Perry MC (2001) Corticosteroids in advanced cancer. Oncology (Williston Park) 15(2):225–234, discussion 234–226 Wooldridge JE, Anderson CM, Perry MC (2001) Corticosteroids in advanced cancer. Oncology (Williston Park) 15(2):225–234, discussion 234–226
22.
go back to reference Yap R, Akhileswaran R, Poh Heng C, Tan A, Hui D (2014) Comfort care kit: use of nonoral and nonparenteral rescue medications at home for terminally Ill patients with swallowing difficulty. J Palliat Med 17(5):575–578PubMedCrossRef Yap R, Akhileswaran R, Poh Heng C, Tan A, Hui D (2014) Comfort care kit: use of nonoral and nonparenteral rescue medications at home for terminally Ill patients with swallowing difficulty. J Palliat Med 17(5):575–578PubMedCrossRef
23.
go back to reference Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31(25):3076–3082PubMedCrossRef Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31(25):3076–3082PubMedCrossRef
24.
go back to reference Yennurajalingam S, Zhang T, Bruera E (2007) The impact of the palliative care mobile team on symptom assessment and medication profiles in patients admitted to a comprehensive cancer center. Support Care Cancer 15(5):471–475PubMedCrossRef Yennurajalingam S, Zhang T, Bruera E (2007) The impact of the palliative care mobile team on symptom assessment and medication profiles in patients admitted to a comprehensive cancer center. Support Care Cancer 15(5):471–475PubMedCrossRef
Metadata
Title
Changes in medication profile among patients with advanced cancer admitted to an acute palliative care unit
Authors
David Hui
Zhijun Li
Gary B. Chisholm
Neha Didwaniya
Eduardo Bruera
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2390-1

Other articles of this Issue 2/2015

Supportive Care in Cancer 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine